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Objective. To identify the routes patients with ovarian cancer take between first symptom presentation and diagnosis. 
Design: Cohort study
Setting: 39 general practices in Devon, UK.
Population: All ovarian cancer patients identified in the practices, with a diagnosis between 200-2007 inclusive.
Methods: All patients had their cancer symptoms, referrals and diagnoses identified and dated using their doctors’ records. . 
Main outcome measures: Numbers of patients taking specific routes to diagnosis, along with the time taken to diagnosis. 
Results: Three main routes to diagnosis emerged. The first was the expected route of outpatient referral; 195 (92% of the total) had at least one of the seven ovarian cancer symptoms or an abdominal mass. 123 (58%) were referred to a specialist, though only 65 (31%) were referred to a gynaecologist. 35 (17%) were initially investigated within primary care by ultrasound scanning, and a further 35 (17%) were admitted as emergencies. 
The interval from first symptom to referral was similar across the different pathways, with a median (inter-quartile range) time between the first symptom presenting to primary care and first investigation / referral being 2.5 (0, 27.5) days. The median interval from first symptom reported in primary care to diagnosis was 74.5 (32, 159) days.
Conclusions: Only a minority of ovarian cancer patients follow the expected route to diagnosis of urgent referral to a gynaecologist. In most women, general practitioners rapidly identified the need to investigate. Avoidable delays generally occurred after the decision to investigate was made.
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Introduction
Around 6,800 new ovarian cancers are diagnosed each year in the UK.1 The UK has one of the highest incidences in Europe, along with Nordic countries.2 Mortality is high, with overall 5-year survival of approximately 35%.3  Survival is very dependent upon stage at diagnosis. In early cancers (FIGO stage I or II) survival is 80-90%, compared with 25% in late cancers (FIGO III and IV).4 Currently only 30% of patients are diagnosed in the early stages.5  Survival is also worse in the UK, when compared with other European countries.6 Reasons for the UK’s relatively poor performance are being sought in a large international comparison, but almost certainly include delays in diagnosis.7 The countries with the worst ovarian cancer mortality include those with the strongest tradition of primary care, and it is possible that the ‘gatekeeping’ role of primary care (whereby access to specialist care is only available through a primary care referral) may contribute to diagnostic delays. Other reasons for diagnostic delays are possible, especially access to investigations. 

No validated screening test is currently available, although trials of screening are ongoing. ADDIN EN.CITE 8-9 Thus, most cancers present initially to primary care, and the main prospect for earlier diagnosis is improved identification of symptomatic cancer.10-11 Until recently, ovarian cancer was considered to have few symptoms. However several recent studies have shown that symptoms are frequent, though they often go unrecognised by women and doctors, due to their non-specific nature. ADDIN EN.CITE 12-14 Abdominal pain, abdominal distension, pelvic pain, increased urinary frequency, constipation or diarrhoea, abnormal vaginal bleeding, weight loss, abdominal bloating and fatigue have all been reported. ADDIN EN.CITE 8 13 15 However, these symptoms are also common in non-malignant conditions; indeed, 95% of women attending primary care have a symptom potentially representing ovarian cancer.11 

If ovarian cancer is suspected, two investigations are available in primary care: CA125 antigen and ultrasound scanning.  CA125 levels were raised at diagnosis in all but 7.6% of women with FIGO III and IV cancers in a secondary care study.16 However, in asymptomatic women invited for screening, only 0.6-0.9% have a persistently raised CA125. ADDIN EN.CITE 9 17 The performance characteristics of CA125 in the symptomatic primary care population (as opposed to the asymptomatic screening population) has not been reported. There is concern about the number of false-positives that could arise from increased use of CA-125, which may be raised in many conditions.18 Although abdominal ultrasound is widely available in primary care, trans-vaginal ultrasound (the preferred imaging modality) is not usually directly available to GPs. Thus, GPs refer patients suspected to have ovarian cancer to a gynaecologist.   Current UK guidance for referral of suspected cancer recommends urgent investigation only for abnormal vaginal bleeding and palpable masses.19  The combination of a relatively rare cancer, which produces symptoms of a low predictive value, allied to patchy investigative services may well be contributing to diagnostic delays, which may in turn have worsened the prognosis. Ovarian cancer has recently been selected as one of the three cancers (along with colorectal and lung) for increased primary care access to investigations, with implementation planned to begin in 2011.

Much investment in cancer diagnostic services involved providing rapid investigation services within the “two-week clinics”. However, this assumes that patients are identified in primary care as being at risk and referred to such clinics. We sought to test this hypothesis by mapping out the pathways patients take from first symptom of ovarian cancer presenting to primary care to diagnosis.  

Methods
This study was nested within a retrospective case-control study aimed at identifying and quantifying clinical features of ovarian cancer.13 All 212 primary ovarian cancer cases aged  40 years, diagnosed during 2000-2007 inclusive, living in Exeter, Mid-Devon or East-Devon, England, were identified from 39 participating general practices in these areas. Anonymised copies of the GP’s records, referral letters, specialist consultations and imaging results were taken. Seven symptoms were found to be independently associated with ovarian cancer in the year before diagnosis: abdominal distension, post-menopausal bleeding, loss of appetite, increased urinary frequency, abdominal pain, rectal bleeding, and abdominal bloating.





The 212 patients with ovarian cancer had a median age of 67 years (inter-quartile range 58.5 to 77.5). The several possible pathways towards diagnosis are shown in the Figure. 

[insert the Figure somewhere near here – currently a separate file]


Seventeen patients (8% of the total) had no features of ovarian cancer recorded in their notes in the year before diagnosis: 13 reported symptoms of their cancer to a non-gynaecological specialist, and were referred to a gynaecologist by that specialist. The remaining four (2%) presented acutely unwell to general practice without specific symptoms of ovarian cancer and were admitted as an emergency, although ovarian cancer was not suspected. The remaining 195 (92% of the total) had at least one of the seven ovarian cancer symptoms described earlier or an abdominal mass. 123 (58%) were referred to a specialist, though only 65 (31%) were referred to a gynaecologist. 35 (17%) women with a symptom of ovarian cancer were admitted to hospital acutely unwell without any prior referral for investigation.  35 (17%) had an ultrasound requested by their GP. The intervals between first symptom, first investigative action (either referral or request of an ultrasound) and diagnosis are shown in the Table. 

Table. Intervals between symptom presentation, referral and diagnosis for ovarian cancer patients presenting  a symptom to primary care.
 

Department 	Time in days between the two events (median, IQR)
	First symptom presented to primary care to referral	Referral to diagnosis	Diagnostic interval
Outpatient 
Gynaecology (n=65)	     0      (0, 22)	     50      (29.5, 88.5)	    79    (44, 152)
Other (n=57)	     3      (0, 33)	     64      (27, 117)	    97    (37, 232)
Emergency          (n=35)	     9      (0, 50)	     11      (3, 23)	    40   (13, 157)
Radiology            (n=35)	     2      (0, 15)	     53     (29, 77)	    57     (38, 108)
Total                  (n=193)	     2.5      (0, 27.5)	     48.5      (17, 89)	    74.5   (32, 159)
Note: two women who had reported symptoms of their cancer to their GP had no investigative action initiated by the GP, their cancer being uncovered by secondary care. Their intervals from 1st symptom in primary care to diagnosis were 167 and 327 days.


The difference in intervals from first symptom to diagnosis (which we call the diagnostic interval from now on) across the three non-emergency categories – gynaecology, other specialities and ultrasound – was of borderline significance (p=0.091, median test 2d.f.).

44 women had a CA125 result in their records, all abnormal: it was not possible to identify whether these had been requested in primary or secondary care. One of these was a week after a woman had been admitted to hospital as an emergency; 13 were in women referred for ultrasound, with three of these more than 30 days after the ultrasound was requested; 10 were in women referred to non-gynaecological specialities, of which all 10 were more than 30 days after the referral. Finally 20 of the abnormal CA125 results were in women referred to a gynaecologist, only 4 of which were 30 days after the referral. It is likely all the CA125 tests taken more than 30 days after the other investigative actions were taken in secondary care.

Discussion
This is the first study to map out the routes to diagnosis taken by women with ovarian cancer. There were three main routes. The majority (58%) were referred by their GP for specialist investigation as outpatients, though almost half of these were to departments other than gynaecology. A further 19% presented as an emergency, though it was not always clear from the records that the primary reason for admission was a suspected ovarian cancer. A smaller group (17%) were initially investigated in primary care with ultrasound, and were referred after an abnormal result was found. Finally, the smallest group was the 6% of women whose diagnosis was made without any apparent primary care input at all. Overall this means that only 48% of the cohort took the standard pathway of either a gynaecological referral or primary care investigation, followed by referral to gynaecology.  Differences in the diagnostic interval were relatively small, and only of borderline significance. GPs identified the need for investigation rapidly in most women, who were referred quickly, although a small but important proportion of women experienced delays in referral. 

Strengths and weaknesses
This is a single cohort from one county in the UK, and may not be typical. It is relatively small. It overlaps the introduction of the first referral guidance for suspected cancer sent to GPs in 2000, and updated in 2005.19 Furthermore, the data originate from the GP records, and any omissions in medical recording of symptom, investigations or referrals will have weakened this study. We also used only the symptoms that were found to be independently associated with ovarian cancer in the main study.13 Although this was a consistent approach, other symptoms have been reported by women – such as fatigue – and were not studied here. 

Comparison with previous literature
No primary care study has identified what proportions of ovarian cancer patients take the different routes to diagnosis. This is especially relevant currently, with recent UK and Danish initiatives to increase availability of imaging in primary care. Much recent work has concentrated on outpatient referrals, and whether patients take the urgent or non-urgent route.  In a large UK study of cancers in 1999 and 2000, Allgar reported that 87% of ovarian cancer patients had seen their GP before diagnosis, a slightly lower percentage than reported here.20  These were self-reports rather than data from GP records, perhaps explaining part of the difference. A recent UK electronic database study also reported that 87% of women had described symptoms of their cancer to general practice, and estimated a median diagnostic interval of 19.5 weeks.14 Taken together, these studies suggest that symptoms are common, and in most women are acted upon swiftly by GPs. As with most cancers, a minority of women experience longer delays, which may contribute to a poor outcome.

Implications of the findings
The main finding is that only a minority of patients take the standard route of GP referral to a gynaecologist. In part this reflects the women admitted as an emergency (roughly the same proportion of patients with colorectal cancer or lung cancers are first diagnosed during an emergency admission).21-22  The other likely explanation is that the symptoms of ovarian cancer are non-specific, and often not easy to attribute to a gynaecological source. This probably explains those patients who were referred to other specialties.. However, most women received rapid recognition that they were ill, and most of the diagnostic interval occurred after investigations were initiated. This argues that diagnostic delays in primary care are more due to sub-optimal access to investigation than GPs failing to recognise the need to investigate. In this respect, recent improvements in NHS provision of imaging are very welcome. 
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